Dose Sparing of Capillary Endothelial Cells for BSH and BPA
In Boron Neutron Capture Therapy (BNCT), boron is selectively taken up by cancer cells and activated in situ by a beam of neutrons. However, boron is also taken up by normal cells in some fixed relationship with boron concentration of blood. The kinetics of boron in tissues may then be related to blood boron kinetics. Normal tissue tolerance dose should not be exceeded in BNCT, so it is important to know the boron concentration in blood and normal tissues in the irradiation volume. Further, it is important to be aware of the dose sparing properties of a given boron compound with respect to the microscopic dose distribution. The short range of the boron neutron capture reaction products and the relatively low rate of capture events is such that microscopic events are described by Poisson statistics and determined by cellular geometry and the achievement or otherwise of dose equilibrium.
KeywordsNeutron Capture Boron Concentration Capillary Endothelial Cell Boron Neutron Capture Therapy Neutron Fluence
Unable to display preview. Download preview PDF.
- 2.B.J. Allen, Maximum therapeutic depth in thermal neutron capture therapy, Strahlcnther Onkol 169: 34–41, 1993.Google Scholar
- 4.W.S. Snyder, M.J. Cook, E.S. Nasset, L.R. Karhausen, G.P. Howells and I.H. Lipton, Report of the task group on reference man, ICRP 23 Pergamon Press 1975.Google Scholar
- 7.P.R. Gavin, F.J. Wheeler, R. Huiskamp, C.E. de Haan and K.H.I. Philipp, Large animal normal tissue tolerance with boron neutron capture: comparison with empirical results with a microdosimetric model, MIT Workshop on Macro and Microdosimetry, Cambridge, USA, 1991.Google Scholar
- 8.R. Huiskamp, P.R. Gavin, J.A. Coderre and F.J. Wheeler, Brain tolerance in dogs to BNCT with borocaptate sodium (BSH) and boronphenylalanine (BPA), these proceedings.Google Scholar